UK government rejects calls for independent inquiry into NICE’s work
This article was originally published in SRA
Executive Summary
The UK government has rejected concerns raised by pharma and biotech companies that the cost-effective approach being followed by the country’s health technology assessment body, the National Institute for Health and Clinical Excellence, may be stifling innovation. It has declined calls for an independent inquiry to assess the long-term impact of NICE’s work on the industry1,2.